Pro-apoptotic and pro-autophagic effects of the aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1555-1584

  Niu, Ning Kui ^a,b,c   Wang, Zi Li ^a   Pan, Shu Ting ^b,d   Ding, Hui Qiang ^a   Au, Giang H T ^b   He, Zhi Xu ^e   Zhou, Zhi Wei ^b,e   Xiao, Guozhi ^f   Yang, Yin Xue ^a   Zhang, Xueji ^g   Yang, Tianxin ^h   Chen, Xiao Wu ⁱ   Qiu, Jia Xuan ^d   Zhou, Shu Feng ^b  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d NANCHANG UNIVERSITY   (China)

^e GUIZHOU MEDICAL UNIVERSITY   (China)

^f RUSH UNIVERSITY   (United States)

^g UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

ALS; Apoptosis; Autophagy; EMT; Osteosarcoma; PI3K Akt mTOR pathway

Indexed keywords

ALISERTIB; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; TRANSCRIPTION FACTOR NRF2; UVOMORULIN; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MITOSIS INHIBITION; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MITOCHONDRION; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; AZEPINES; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84928243694     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S74197     Document Type: Article

References (53)

1. Marulanda GA, Henderson ER, Johnson DA, Letson GD, Cheong D. Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control. 2008;15(1):13–20.
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–1543.
3. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:7, 320–5.
4. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. In: Jaffe, Bruland OS, Bielack S, editors. Pediatric and Adolescent Osteosarcoma. Springer; 2010:3–13.
5. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: State of the art. Cancer Metastasis Rev. 2009;28(1–2):247–263.
6. Bielack S, Carrle D, Casali PG; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137–139.
7. Yang G, Yuan J, Li K. EMT transcription factors: Implication in osteosarcoma. Med Oncol. 2013;30(4):697.
8. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89–99.
9. Chaabane W, User SD, El-Gazzah M, et al. Autophagy, apoptosis, mitoptosis and necrosis: Interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz). 2013;61(1):43–58.
10. Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol. 2013;2013:102735.
11. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One. 2013;8(1):e55096.
12. Zou Z, Yuan Z, Zhang Q, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 2012;8(12):1798–1810.
13. Fimia GM, Piacentini M. Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol Life Sci. 2010;67(10):1581–1588.
14. Marquez RT, Xu L. Bcl-2: Beclin 1 complex: Multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res. 2012;2(2):214–221.
15. Erlich S, Mizrachy L, Segev O, et al. Differential interactions between Beclin 1 and bcl-2 family members. Autophagy. 2007;3(6):561–568.
16. Yan A, Wang L, Xu S, Xu J. Aurora-A kinase inhibitor scaffolds and binding modes. Drug Discov Today. 2011;16(5–6):260–269.
17. Kitzen JJ, de Jonge MJ, Verweij J. Aurora kinase inhibitors. Crit Rev Oncol Hematol. 2010;73(2):99–110.
18. Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32(1):44–50.
19. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786(1):60–72.
20. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137(4):609–622.
21. Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008;10(6):676–687.
22. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol. 2010;22(2):181–185.
23. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2010;55(1):26–34.
24. Yuan CX, Zhou ZW, Yang YX, et al. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther. 2015;9:487–508.
25. Ding YH, Zhou ZW, Ha CF, et al. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther. 2015;9:425–464.
26. Tsai JH and Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27(20):2192–2206.
27. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13(4):225–238.
28. Byles V, Zhu L, Lovaas JD, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31(43):4619–4629.
29. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–1657.
30. Hu X, Moscinski LC. Cdc2: A monopotent or pluripotent CDK? Cell Prolif. 2011;44(3):205–211.
31. Warfel NA, El-Deiry WS. P21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52–58.
32. Estaquier J, Vallette F, Vayssiere J-L, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012;942:157–183.
33. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479–489.
34. Klionsky DJ, Emr SD. Cell biology – Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717–1721.
35. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13(9):679–692.
36. Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4(9–10):342–359.
37. Zhang X, Tang N, Hadden TJ, Rishi AK. Rishi, Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011;1813(11):1978–1986.
38. Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344–1348.
39. Mester J, Eng C. When overgrowth bumps into cancer: The PTEN-opathies. Am J Med Genet C Semin Med Genet. 2013;163C(2):114–121.
40. Cannito S, Novo E, Di Bonzo LV, Busletta C, Colombatto S, Parola M. Epithelial-mesenchymal transition: From molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal. 2010;12(12):1383–1430.
41. Ng F, Tang BL. Sirtuins’ modulation of autophagy. J Cell Physiol. 2013;228(12):2262–2270.
42. Bellot GL, Liu D, Pervaiz S. ROS, autophagy, mitochondria and cancer: Ras, the hidden master? Mitochondrion. 2013;13(3):155–162.
43. Dodson M, Darley-Usmar V, Zhang J. Cellular metabolic and autophagic pathways: Traffic control by redox signaling. Free Radic Biol Med. 2013;63:207–221.
44. Kaminskyy VO, Zhivotovsky B. Free radicals in cross talk between autophagy and apoptosis. Antioxid Redox Signal. 2014;21(1):86–102.
45. Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 2013;34(6):340–346.
46. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
47. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116.
48. Denton D, Nicolson S, Kumar S. Cell death by autophagy: Facts and apparent artefacts. Cell Death Differ. 2012;19(1):87–95.
49. Chen Y, Yu L. Autophagic lysosome reformation. Exp Cell Res. 2013;319(2):142–146.
50. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143–153.
51. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19(3):292–315.
52. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–939.
53. Shin K, Margolis B. ZOning out tight junctions. Cell. 2006;126(4):647–649.